Amgen's strategic growth through M&A and R&D investments has led to a diversified portfolio. Find out why I give AMGN stock a ...

Amid all the volatility, some companies are proving resilient by performing much better than the market. Some of these look ...

In the latest trading session, Amgen (AMGN) closed at $277.29, marking a -1.89% move from the previous day. This change lagged the S&P 500's 0.13% gain on the day. At the same time, the Dow lost 1.33% ...

Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the United States against Amgen ...

Alston & Bird allege their client has suffered more than $1 billion in lost sales from being unable to manufacture a ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...

Alston & Bird allege their client has suffered more than $1 billion in lost sales from being unable to manufacture a ...

Despite resilient demand, healthcare has taken a hit along with the rest of the market. Amgen could boost profits ...

Originally approved by the FDA in 1998, Amgen’s Enbrel is still sailing along without facing biosimilar competition in the ...

In his 13 years as CEO at Amgen, Robert Bradway has seen many of his counterparts at other major biopharma companies come and ...

In this week’s edition of InnovationRx, we look at the impact of Medicaid cuts, a $400 million obesity bet, a study of bias ...

Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.